[1] INFARMED: Decreto-Lei n.º 307/2007, de 31 de agosto;
[2] INFARMED: Decreto-Lei n.º 171/2012, de 1 de agosto;
[3] INFARMED: Deliberação n.º 2473/2007, de 28 de novembro,
[4] INFARMED: Decreto-Lei n.º 18/90, 27 de dezembro;
[5] INFARMED: Decreto-Lei n.º 172/2012, de 1 de agosto;
[6] INFARMED: Portaria nº 137-A/2012, de 11 de maio;
[7] INFARMED: DL nº 112/2011, de 29 de novembro;
[8] INFARMED: Decreto-Lei n.º 152/2012, de 12 de julho;
[9] INFARMED: Decreto-Lei n.º 198/2012 de 24 de agosto;
[10] INFARMED: Decreto-Lei n.º176/2006, de 30 de agosto;
[11] INFARMED: Decreto-Lei n.º 20/2013, de 14 de fevereiro;
[12] INFARMED: Portaria n.º 137-A/2012, de 11 de maio;
[13] INFARMED: Despacho n.º 15700/2012, de 30 de novembro;
[14] INFARMED: Lei n.º 11/2012, de 8 de março;
[15] Portaria n.º 224-A/2013 de 9 de julho;
[16 INFARMED: Decreto-Lei nº 242/2000, de 26 de setembro;
[17] INFARMED: Decreto-Lei nº 271/2002, de 2 de dezembro;
[18] INFARMED: Decreto-Lei n.º 103/2013, de 26 de junho;
[19] INFARMED: Decreto-Lei n.º 15/93, de 22 de janeiro;
[20] INFARMED: Lei 13/2012, de 26 de março;
[21] INFARMED: Portaria n.º 594/2004, de 2 de junho;
[22] INFARMED: Deliberação n.º 1500/2004, de 7 de dezembro;
[23] INFARMED: Portaria n.º 769/2004, de 1 de julho;
[24] INFARMED: Decreto-Lei n.º 48-A/2010, de 13 de maio;
Parte II – Atividades desenvolvidas no estágio
[1] Carrilho MJ, Patrício L (2002). “A situação demográfica recente Em Portugal”; Revista de
Estudos Demográficos; Nº.32, Lisboa, INE, 101-145.
[2] Barreto A, (1996). “Três décadas de mudança social”. In: Barreto A, eds. A situação social
em Portugal; Lisboa, ICS, 35-60.
[3] Bengston VL, (2001), “Beyond the nuclear family: the increasing importance of multigenerational bonds.”. Journal of Marriage and Family; 63: 1-16;
[4] Almeida MF, (2009). “Promoção da Saúde depois dos 65 anos. Elementos para uma política integrada de envelhecimento.” Lisboa: ENSP/UNL. Dissertação de Doutoramento.
[5] INE, Censos 2011 – Resultados provisórios. Lisboa, INE. ISSN 2182-4215. Acessível em: www.censos.ine.pt [acedido em 10 Setembro de 2014]
[6] Vaz E, Silva LF, Alves F, Vieira C, Sousa F, Silva T et al (2004), “Reconfiguração da concepção de velhice em Portugal”. In: VIII Congresso Luso-Afro-Brasileiro de Ciências Sociais; Setembro 2004; Universidade de Coimbra; 1-9
[7] Ferreira S (2008). “A questão social e as alternativas da sociedade civil no contexto das novas formas de governo”. Ciências Sociais Unisinos; 4 (1):28-38.
[8] Araújo LF, Coutinho MPL, Carvalho VAML (2005). Social representation of the old age among elderly people who take part in groups of living together. Psicol. Psicologia ciência e
profissão; 25 (1):118-131.
[9] Bostock S, Steptoe A, (2012). Association between low functional health literacy and mortality in older adults: longitudinal cohort study. British Medical Journal; 344: 1-10.
[10] Sousa L. (2009), The multigenerational family and the elderly: a mutual or parasitical symbiotic relationship? In: Sousa L, eds; Families in Later Life: Emerging Themes and Challenges; Nova Science Publishers; New York; 27-48.
[11] Sousa L, Silva A, Marques F, Santos L (2009), Constructing family integrity in later life. In
[12] Diogo, MJDE (1997). A dinâmica dependência-autonomia em idosos submetidos à amputação de membros inferiores. Revista Latino-Americana Enfermagem - Ribeirão Preto; 5 (1):59-64.
[13] Direcção Geral da Saúde Lisboa (2010) - Elementos Estatísticos Saúde/2008 ISSN 0872- 1114 Acessível em: http://www.dgs.pt [acedido em 10 Setembro de 2014]
[14] Araújo LF, Coutinho MPL, Santos MFS (2006). O idoso nas instituições gerontológicas: um estudo na perspectiva das representações sociais. Psicologia e Sociedade; 18 (2):89-98.
[15] Sousa S et al (2012). As Instituições Particulares de Solidariedade Social num contexto de crise económica. Lisboa: IPI-Consulting Network Portugal, CNIS e Fundação Millenium BCP.
[16] Tarricone R, Agos DT (2008). Home Care in Europe: The Solid Facts. Genéve: OMS- UMCCI.
[17] SNIPH (Swedish National Institute of Public Health) (2007)- Healthy Ageing: a Challenge for Europe, Brussels Estocolmo.
[18] MacKeigan LD, Marshman JÁ, Einarson TR (2001). The Role of the Pharmacist in Home Care: background paper. Ottawa: Canadian Pharmacists Association.
[19] Zilich AJ, McDonough RP, Carter BL, Doucette WR (2004). Influential characteristics of a Physician/ Pharmacist Collaborative Relationships. Annals of Pharmacotherapy; 38: 764-70.
[20] Chodzko ZW, Schwingel A, Park C (2008). Successful aging: the role of physical activity.
American Journal of Lifestyle Medicine; 3: 1-9.
[21] Meneses AS (2012);. Pharmaceutical care of the elderly: Basis and proposals. SBGG.
[22] Palmio J, Udd B (2014). Borderlines between sarcopenia and mild late-onset muscle disease. Frontiers in Aging Neuroscience; 267 (6): 1-9.
[23] Care P (2012). Medicines in the elderly., Pharmaceutical Press: UK.
[24]. Bolignano D, Mattace RF, Sijbrands EJG, Zoccali C (2014). The aging kidney revisited: A systematic review. Ageing Research Reviews; 14: 65-80.
[25] London G, Covic A, Goldsmith D, Wiecek A, Suleymanlar G, Ortiz A et al (2011). Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ
flow—implications for CKD and cardiovascular disease. Kidney International Supplements; 1:10-12.
[26] Makowski MR, Henningsson M, Spuentrup E, Kim WY, Maintz D, Manning WJ et al (2013). Characterization of Coronary Atherosclerosis by Magnetic Resonance Imaging. Circulation; 128:1244-1255
[27] Wong BW, Meredith A, Lin D, McManus BM (2012). The Biological Role of Inflammation in Atherosclerosis. Canadian Journal of Cardiology; 28: 631–641.
[28] Haq K, McElhaney JE (2014). Ageing and respiratory infections: The airway of ageing.
Immunology Letters; 5539:1-6.
[29] Ruivo S, Viana P, Martins C, Baeta C (2009). Efeito do envelhecimento cronológico na função pulmonar. Comparação da função respiratória entre adultos e idosos saudáveis. Revista
Portuguesa de Pneumologia; 15(4): 629-653.
[30] Meireles AE, Pereira LMS, Oliveira TG, Christofoletti G, Fonseca AL (2010). Alterações neurológicas fisiológicas ao envelhecimento afetam o sistema mantenedor do equilíbrio.
Revista Neurociências; 18(1):103-108.
[31] Rosa GR, Camargo EAF (2014). Polimedicação em Idosos. Interciência & Sociedade; 3(2):72-78
[32] Turnheim K. (2003). When drug therapy gets old: :pharmacokinetics and pharmacodynamics in the elderly. Experimental Gerontology; 38 (8): 843-53.
[33] Cusack B.J. (2004). Pharmacokinetics in older persons. The American Journal of Geriatric
Pharmacotherapy; 2 (4): 274-302.
[34] Eldesoky, E.S. (2007). Pharmacokinetic-pharmacodynamic crisis in the elderly.The American Journal of Geriatric Pharmacotherapy; 14(5): 488-98.
[35] Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet. 2008; Volume 47(5); 297-321.
[36] Bowie, MW; Slattum, PW. (2007). Pharmacodynamics in older adults: a review.
The American Journal of Geriatric Pharmacotherapy; 5 (3): 263-303.
processes. Journal of Psychosocial Nursing and Mental Health Services; 47 (10): 15-6, 17-8.
[38] Mangoni, A. A.; Jackson, S. H. D. (2003). Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. British Journal of Clinical
Pharmacology; 57 (1): 6–14.
[39] Delafuente, JC. (2008). Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. Consult Pharm Journal 23 (4): 324-34.
[40] Iotz U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug
Metabolism Reviews; 41(2); 67-76.
[41] Bayliss EA, Ellis JL, Steiner JF (2007). Barriers to Self-Management and Quality-of-Life Outcomes in Seniors With Multimorbidities. Annals of family medicine; 5(1):395-402.
[42]. Santos M, Almeida A (2010). Polimedicação no idoso. Revista de Enfermagem
Referência; 3(2):149-162.
[43] Silva P, Luís S, Biscaia A. (2004). Polimedicação: um estudo de prevalência nos Centros de Saúde do Lumiar e de Queluz. Revista Portuguesa de Clínica Geral; 20: 323‑36.
[44] Sergi G, De Rui M, Manzato E. (2011). Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use?. Drugs Aging; 28 (7): 509‑18.
[45] Brulhart MI, Wermeille JP (2011). Multidisciplinary medication review: evaluation of a pharmaceutical care model for nursing homes. International Journal of Clinical Pharmacology; 33 (3):549-57
[46] Vogt-Ferrier N (2011). Older patients, multiple comorbidities, polymedication… should we treat everything?. European Geriatric Medicine; 2:48-51.
[47] INFOMED: Base de dados de medicamentos - Venlafaxina. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[48] INFOMED: Base de dados de medicamentos - Mirtazapina. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[49] INFOMED: Base de dados de medicamentos - Trazodona. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[50] Shad UM, Carmichael CA, Preskorn SH, Horst WD (1999) The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clinical
Pharmacology Therapy; 65:183
[51] Kuzmicic J, Parra V, Verdejo HE, López-Crisosto C, Chiong M, García L, Jensen MD et al (2014). Trimetazidine prevents palmitate-induced mitochondrial fission and dysfunction in cultured cardiomyocytes. Biochemical Pharmacology; 91(3):323-36
[52] INFOMED: Base de dados de medicamentos - Trimetazidina. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[53] Wilting, I.; Movig, K.L.; Moolenaar, M.; Hekster YA, Brouwers JR, Heerdink ER, et al (2005). Drug-drug interactions as a determinant of elevated lithium serum levels in daily clinical practice. Bipolar Disorders; 7, (3): 274-80.
[54] INFOMED: Base de dados de medicamentos – Carbonato de Lítio. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[55] INFOMED: Base de dados de medicamentos – MADOPAR®. Acessível em: http://www.infarmed.pt. [acedido em 15 Agosto de 2014].
[56] Gaziano, J.M.; Gibson, C.M. (2006). Potential for drug-drug interactions in patients taking analgesics for mild-tomoderate pain and low-dose aspirin for cardioprotection. The American
Journal of Cardiology; v.8, n.97 (9A), p.23-9.
[57] Wynn, R.L.; Cook, J. (2006). Does ibuprofen block the cardioprotective effects of aspirin in dental patients? European Journal of General Dentistry; v.54, n.1, p.6, 8-9.
[58] Hippisley-Cox, J.; Coupland, C.; Logan, R. (2005). Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti- inflammatory drugs: population based nested case-control analysis. British Medical Journal; v. 3, n.331(7528), p.1310-6.
[59] Boyer EW, Shannon M (2005). The Serotonin Syndrome. The New England Journal of
Medicine; 11:352-356.
[60] Iqbal MM, Basil MJ, Kaplan J, Iqbal T (2012). Overview of serotonin syndrome. Annals of
Clinical Psychiatry; 24(4):310-318.
triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids in
Health and Disease ; 13:73
[62] Schatzberg A (1998). Bipolar Disorder: recent issues in diagnosis and classification. Journal of Clinical Psychiatry ; 59 (suppl 6);13-9.
[63] Boyer E, Shannon M (2005). The serotonina syndrome. The New England Journal of
Medicine; 352 (11): 1112-20
[64] Isbister GK, Buckley NA, Whyte IM (2007). Serotonine toxicity: a pratical aapproach to diagnosis and treatment. British Medical Journal; 187 (6): 361-5
[65] Spijker J, Nolen WA (2011). The algorithm for the biological treatment of depression in the Dutch multidisciplinary guideline on depression. Tijdschrift voor psychiatrie; 53 (4):223-33.
[66] INFOMED: Base de dados de medicamentos – WELLBUTRIN XR®. Acessível em: http://www.infarmed.pt. [acedido em 10 Outubro de 2014].
[67] Gemma GP, Blanco JP (2011). Role of bupropion in the treatment of resistant depression: Management of bupropion in combination therapy. Actas españolas de psiquiatría; 39 (2):8-13.
[68] Larochelle P, Tobe SW, Lacourcière Y (2014). β-Blockers in hypertension: studies and meta-analyses over the years. The Canadian Journal of Cardiology; 30 (5):16-22.
[69] INFOMED: Base de dados de medicamentos – Bisoprolol. Acessível em: http://www.infarmed.pt. [acedido em 10 Outubro de 2014].
[70] Deedwania P (2013). Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure. Drugs; 73 (14):1569-86.
[71] Potter WZ, Hollister LE (1998). Antipsychotic agents and lithium. Basic and clinical
pharmacology; (7) 464-82.
[72] Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines team for Bipolar Disorder (2004). Australian and New Zealand Clinical Practice Guidelines for the treatment of bipolar diosrder. Australian and New Zealand Journal of Psychiatry; 38: 280- 305.
[73] Roger SM, Yoon J, Jerrell JM, Liauw SS (2011). Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatric Disease and Treatment; (7) 319–323
[74] Wójcikowski J, Basinska A, Boksa J, Daniel WA (2014). The influence of amitriptyline and carbamazepine on levomepromazine metabolism in human liver: An in vitro study.
Pharmacological Reports; 66:1122-1126.
[75] INFOMED: Base de dados de medicamentos – Aripripazol. Acessível em: http://www.infarmed.pt. [acedido em 10 Outubro de 2014].
[76] Tohen M, Sanger T, McElroy S et al (1999). Olanzapine versus placebo in the treatment of acute mania. The American Journal of Psychiatry ; 156: 702-9
[77] Vandel B, Vandel S, Allers G, Bechtel P, Volmat R (1979). Interaction Between Amitriptyline and Phenothiazine in Man: Effect on Plasma Concentration of Amitriptyline and its Metabolite Nortriptyline and the Correlation with Clinical Response. Psychopharmacology; 65:187-190.
[78] INFOMED: Base de dados de medicamentos – Olanzapina. Acessível em: http://www.infarmed.pt. [acedido em 25 Agosto de 2014].
[79] Prior TI, Baker GB (2003). Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci; 28(2):99-112.
[80] 2012. Antidepressivos no Transtorno Depressivo Maior em Adultos. BRATS; 6(18).
[81] Oliveira DAAP, Gomes L, Oliveira RF (2006). Prevalência de depressão em idosos que freqüentam centros de convivência. Rev Saúde Pública; 40(4):734-6.
[82] Martinez PAS, Trevino LJ, Mesa EMD,Gonzalez MPGP, Gonzalez PM, Al-Halabi S,et al (2014). Patología dual en trastornos de ansiedad:recomendaciones en el tratamiento farmacológico. Addiciones; 26(3):254-277.
[83] Pohl RB, Feltner DE, Fieve RR, Pande AC (2005). Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology ; 25(2):151-8.
[84] INFOMED: Base de dados de medicamentos – Pregabalina. Acessível em: http://www.infarmed.pt. [acedido em 25 Agosto de 2014].
[85] Costa IC, Carvalho HN, Fernandes L (2013). Aging, circadian rhythms and depressive disorders: a review. Am J Neurodegener Dis; 2(4):228-246.
[86] Laudon M, Frydman-Marom A (2014). Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders. Int. J. Mol. Sci; 15:15924-15950.
[87] Neves GSL, Giorelli AS,Florido P, Gomes MM (2013). Transtornos do sono: visão geral.
Rev Bras Neurol; 49(2):57-71.
[88] TUA SAÚDE: Suplementos de melatonina. Acessível em: http://www.tuasaude.com/ [acedido em 25 Agosto de 2014].
[89] Silva P (2012). Velhos e novos anticoagulantes orais. Perspetiva farmacológica. Rev Port
Cardiol; 31(1):6-16.
[90] Miao L, Yang J, Huang C, Shen Z (2007). Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.Eur J Pharmacol; 63(12):1135-1141.
[91] Lane MA, Devine ST, McDonald JR (2012). High-risk Antimicrobial Prescriptions Among Ambulatory Patients on Warfarin. J Clin Pharm Ther; 37(2):157-160.